Major Accountabilities
Leads the BR TCO China organization in accordance with the global BR TCO clinical strategy, including its targeted build over time, providing strategic and operational steer.
-
Oversees the selection and prioritization of compounds/modalities to be developed in China ensuring alignment with Global BR TCO, China Development and China Oncology Business Unit.
-
Provides scientific and clinical input on internal and external assets and portfolio areas based on a deep understanding of local life sciences environment and TCO strategy:
-
Represents TCO in Business Development and Licensing (BD&L) due diligence reviews and integrations, managing Novartis and external stakeholders in China.
-
Develops relationships and partnerships in assessing external capabilities in early oncology and explores innovative drug development models in China to shorten the gap of registration timeline between China and global.
-
Identifies opportunities for the introduction of new technologies and spearheads their introduction into TCO programs in China and globally.
- Leads or helps oversee external collaborations, partnering closely with global colleagues across the company.
-
Drives China’s contribution to early oncology development globally through the strategic incorporation of regional and global elements key to Novartis success in China and Asia.
-
Ensures TCO trials are being prepared and conducted scientifically, safely and successfully by ensuring adequate resourcing and support to the TCO China team
-
Interacts with the scientific and medical community to establish a qualified network of TCO first-in-human and proof-of-concept sites in China. Build and maintain collaborative relationships with PIs and KOLs who will be engaged long-term for advice and advocacy on the Novartis discovery and early development oncology pipeline in China.
-
Represents Novartis early oncology in China in interactions with the regulatory agency NMPA, with HGRAC and with other authorities and decision-making bodies as appropriate.
-
Provides local leadership for TCO associates and managers in China, guiding their development and engagement
-
Ensures all activities of associates comply with Novartis China company standards and local regulations
Ideal Background
Education
(minimum)
MD degree and PhD-level basic science required (PhD not required). MD / PhD preferred. Board Certification (or equivalent expertise) in Hematology-Oncology (heme-onc).
Oncology experience required
People management experience required.
Languages:
Fluent Mandarin for verbal and written communication required
Fluent English for verbal and written communication required
Experience/
Professional requirement:
-
Helps maintain and create a competitive edge and ensures that Novartis is seen as a credible, ethical, and preferred partner.
- Recognized as a Heme-Onc expert with a substantial record of quality scientific publications and international recognition for expertise.
- Interpretation of preclinical data in hematology/oncology (molecular biology, pharmacology, pharmacokinetics, and toxicology).
- Working knowledge of the application of Pharmacokinetics (PK) / Pharmacodynamics (PD) and biostatistics to clinical development and trials.
- Proven ability to analyze and interpret efficacy and safety data relating to oncology.
-
Working knowledge of Good Clinical Practice and regulatory requirements relating to clinical trials and oncology.
-
Proven ability to manage, develop and coach people.
-
Strong interpersonal skills for bridging scientific, operational and business stakeholders.
-
Experience working in a multicultural global organization.
-
Excellent personal ethical integrity and a commitment to improving the outcomes for patients with malignancies.
